Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years

Siponimod significantly reduced the risk of confirmed disability progression (CDP), worsening in cognitive processing speed (CPS), relapses, and magnetic resonance imaging (MRI) measures of brain atrophy and inflammation versus placebo in secondary progressive multiple sclerosis (SPMS) patients in t...

Full description

Bibliographic Details

Published in:	Multiple sclerosis Vol. 28; no. 10; p. 1591
Main Authors:	Cree, Bruce Ac, Arnold, Douglas L, Fox, Robert J, Gold, Ralf, Vermersch, Patrick, Benedict, Ralph Hb, Bar-Or, Amit, Piani-Meier, Daniela, Rouyrre, Nicolas, Ritter, Shannon, Kilaru, Ajay, Karlsson, Goeril, Giovannoni, Gavin, Kappos, Ludwig
Format:	Journal Article
Language:	English
Published:	England 01.09.2022
Subjects:	Atrophy Azetidines Benzyl Compounds Humans Multiple Sclerosis - drug therapy Multiple Sclerosis, Chronic Progressive - drug therapy Multiple Sclerosis, Relapsing-Remitting - drug therapy Recurrence confirmed cognitive worsening cortical gray matter S1P modulator secondary progressive multiple sclerosis Confirmed disability progression siponimod
ISSN:	1477-0970, 1477-0970
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!